Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07460622 · ClinicalTrials.gov registry record · NA
A Virtual Reality E-cigarette Prevention and Emotion Regulation Intervention for Adolescents
A NA study, sponsored by Yale University.
- Not yet
- Registry status
- NA
- Development phase
- 1,251
- Enrollment target
NCT07460622: Clinical Trial NA study, sponsored by Yale University.
NCT07460622 is a NA study that has not yet begun recruiting, run by Yale University. The registered enrollment target is 1,251 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (11% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07460622, a NA study, has not yet begun recruiting, sponsored by Yale University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 1,251 participants
- Enrollment target
Study Summary
This study will examine E-Invite Only VR, a novel school-based universal e-cigarette prevention intervention that uses virtual reality (VR) to deliver prevention and emotion regulation skills-building content to middle school students in real-world classrooms. If successful, E-invite Only VR has the potential to prevent adolescents from experiencing a multitude of poor health outcomes related to nicotine vaping, including cancer.
Primary Outcome
E-cigarette use is defined as answering "yes" to the question: "Have you ever used an e-cigarette, even once or twice?" Participants will be classified as having initiated e-cigarette use if they report any past use at any of these time points.
Interventions
- BEHAVIORAL Virtual Reality E-Cigarette Prevention Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,251 participants |
| Start Date | 2026-10-01 |
| Est. Completion | 2028-06 |
| Phase | NA |
What is known before NCT07460622 opens enrollment
NCT07460622 is an interventional study that assigns participants to a tested intervention. Its 1,251 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (11% lower).
The record links to 0 conditions, and to 1 intervention - of which Virtual Reality E-Cigarette Prevention Program is the first listed.
NCT07460622 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07460622 about?
NCT07460622 is a clinical study titled "A Virtual Reality E-cigarette Prevention and Emotion Regulation Intervention for Adolescents". This study will examine E-Invite Only VR, a novel school-based universal e-cigarette prevention intervention that uses virtual reality (VR) to deliver prevention and emotion regulation skills-building content to middle school students in real-world classrooms. If successful, E-invite Only VR has the...
What is the current status of trial NCT07460622?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 1,251 participants. The study started on 2026-10-01. Estimated completion is 2028-06.
What interventions are being tested in trial NCT07460622?
The interventions under investigation include: Virtual Reality E-Cigarette Prevention Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT07460622?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07460622's enrollment target sits among peer trials
1,251 80th of 2000 higher than 1,921 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02743858 · 1,250 participants
Lymphedema Surveillance Study
- NCT04670874 · 1,250 participants
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
- NCT04807868 · 1,250 participants
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
- NCT05995821 · 1,250 participants
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI